Cirazolin

Cirazolin
	2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1H-imidazole
Identifikacija
CAS registarski broj	59939-16-1
PubChem	2765
ChemSpider	2663
MeSH	cirazoline
ChEMBL	CHEMBL13852
IUPHAR ligand	515
Jmol-3D slike	Slika 1
SMILES
	O(c1c(cccc1)C2CC2)CC/3=N/CCN\3
InChI
	InChI=1S/C13H16N2O/c1-2-4-12(11(3-1)10-5-6-10)16-9-13-14-7-8-15-13/h1-4,10H,5-9H2,(H,14,15) ; Kod: YAORIDZYZDUZCM-UHFFFAOYSA-N InChI=1/C13H16N2O/c1-2-4-12(11(3-1)10-5-6-10)16-9-13-14-7-8-15-13/h1-4,10H,5-9H2,(H,14,15); Kod: YAORIDZYZDUZCM-UHFFFAOYAV
Svojstva
Molekulska formula	C13H16N2O
Molarna masa	216.279
	(šta je ovo?) (verifikuj) ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

Cirazolin je neselektivni agonist alfa-1 adrenergičkog receptora (α1-AR), i antagonist alfa-2 adrenergičkog receptora^[5]. Smatra se da ova kombinacija osobina može da učini cirazolin efektivnim vazokonstriktorom^[5].

Za cirazolin je takođe pokazano da umanjuje unos hrane kod pacova, što je potencijalno posledica aktivacije alfa 1-adrenoceptora u paraventrikularnog jezgra u hipotalamusa^[6].

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
1 2 Ruffolo Jr, RR; Ruffolo and Waddell (1982). „Receptor interactions of imidazolines. IX. Cirazoline is an alpha-1 adrenergic agonist and an alpha-2 adrenergic antagonist”. J Pharmacol Exp Ther. 222 (1): 29–36. PMID 6123592.
↑ Davies, BT; Davies BT, Wellman PJ (1992). „Effects on ingestive behavior in rats of the alpha 1-adrenoceptor agonist cirazoline”. Eur J Pharmacol. 210 (1): 11–16. DOI:10.1016/0014-2999(92)90645-K. PMID 1350985.

Vanjske veze

Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[ruffolo-5] 1 2 Ruffolo Jr, RR; Ruffolo and Waddell (1982). „Receptor interactions of imidazolines. IX. Cirazoline is an alpha-1 adrenergic agonist and an alpha-2 adrenergic antagonist”. J Pharmacol Exp Ther. 222 (1): 29–36. PMID 6123592.

[davies-6] Davies, BT; Davies BT, Wellman PJ (1992). „Effects on ingestive behavior in rats of the alpha 1-adrenoceptor agonist cirazoline”. Eur J Pharmacol. 210 (1): 11–16. DOI:10.1016/0014-2999(92)90645-K. PMID 1350985.

[1]

[2]

[3]

[4]

[5]

[6]